Compare Booking Holdings Inc (BKNG) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booking Holdings Inc vs Enveric Biosciences Inc — how do they compare? Booking Holdings Inc trades at $211.35 (market cap $159.95B), while Enveric Biosciences Inc trades at $1.59 (market cap $6.20M). The key difference: Booking Holdings Inc is far larger — about 25798.4× Enveric Biosciences Inc's market cap, and Booking Holdings Inc pays a 0.79% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| BKNG | ENVB | |
|---|---|---|
Market Cap | $159.95B | $6.20M |
Sector | Consumer Cyclical | Health |
52-Week High | $228.83 | $17.40 |
52-Week Low | $154.13 | $1.27 |
Enterprise Value | $163.43B | $1.30M |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booking Holdings (BKNG) trades at $211.73, down 0.54% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating EPS estimates at $2.54 versus $2.43 expected, driven by resilient travel demand. Revenue grew to $26.92B in 2025, with a net income margin of 25.53%, while cash flow from operations remains robust at $9.41B. Analyst consensus is strongly bullish with a $239.31 price target.
Outlook is positive given earnings beats and travel recovery, but risks include geopolitical volatility and high valuation multiples. The stock offers growth potential with a wide moat in online travel, though debt levels and competitive pressures warrant monitoring. Institutional sentiment supports upside, with 64% of analysts rating it Buy.
ENVB trades at $1.59, up 3.25% today, with a bullish technical signal driven by moving averages. The company, a biotechnology firm developing neuroplastogenic therapeutics, reported significant earnings beats in all quarters of 2025, including a positive EPS of $0.85 in Q4 versus an expected loss. Recent news highlights progress with its lead candidate EB-003, including non-hallucinogenic profile confirmations and FDA guidance alignment, though financials show negative ROE and ROA with net income of -$8.77M in 2025.
The outlook is cautiously optimistic due to strong analyst support (75% buy ratings) and clinical advancements, but high financial losses and reliance on financing cash flow pose risks. Stock performance hinges on successful drug development milestones and future profitability, with current sentiment buoyed by technical strength and positive pipeline updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
